To examine the genetic therapeutic efficiency of targeting tubular Mydgf in mice with AAN, we delivered tubule‐specific AAV serotype 9 harboring Mydgf (pAAV9‐Ksp‐cadherin‐Mydgf) via a tail vein injection into mice (Figure3a). Here, MYDGF is linked to Balkan nephropathy.